![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260915_LB_Pharmaceuticals_Leadership_Tracker-768x512.png\"){kind=tracking}
<\/p>\n<\/p>\n
Company:<\/strong> LB Pharmaceuticals \u00b7 Event Type:<\/strong> Executive Appointment \u00b7 New CMO:<\/strong> Susan G. Kozauer, M.D. \u00b7 Context:<\/strong> NOVA 2 Phase 3 Schizophrenia Readout Expected H1 2027 \u00b7 Date:<\/strong> September 15, 2026 (effective September 14)<\/p>\n LB Pharmaceuticals appointed Susan G. Kozauer, M.D., chief medical officer effective September 14 and announced the appointment on September 15. She succeeds Anna Eramo, M.D., who resigned as CMO effective June 15 for personal reasons and remained a full-time consultant through September 15. Kozauer arrives while LB Pharmaceuticals is running the pivotal NOVA 2 study of LB-102 in schizophrenia, with topline data expected in the first half of 2027. The transition restores a permanent CMO but does not independently change the trial design, timing or probability of success.<\/p>\n The filed appointment agreement provides a September 14 start date, a $515,000 annual base salary, a 40 percent target bonus, a $150,000 sign-on bonus and, subject to board approval, an option for 200,000 shares vesting over four years. Kozauer most recently led clinical development at Centessa Pharmaceuticals and previously worked on adult and pediatric development of lumateperone at Intra-Cellular Therapies. The company announcement links her remit to LB-102 and the NOVA 2 readout. Eramo’s earlier filing stated that her departure was unrelated to clinical operations or practices and that she would advise through September 15; her destination after that consulting period was undisclosed.<\/p>\n Bull case:<\/strong> A planned succession with meaningful continuity \u2014 the predecessor’s three-month consulting period ends as the incoming CMO begins, and the company had publicly disclosed a replacement search. Kozauer’s late-stage neuropsychiatry and regulatory experience is relevant to data review, safety interpretation and potential pre-NDA preparation.<\/p>\n Bear case:<\/strong> Execution risk concentrated around a single late-stage asset. A new medical leader may sharpen governance before a pivotal readout, but leadership onboarding during an active Phase 3 program can also create review and coordination demands; the company did not describe responsibilities transferred, protocol amendments or regulator interactions.<\/p>\n LB Pharmaceuticals is a late-stage neuromedicines company centered on LB-102, an oral N-methyl derivative of amisulpride. The small molecule selectively antagonizes dopamine D2 and D3 receptors and serotonin 5-HT7 receptors. NOVA 2 is a randomized, double-blind, placebo-controlled U.S. Phase 3 study of approximately 460 adults with an acute exacerbation of schizophrenia, comparing 50 milligrams, 100 milligrams and placebo for six weeks; change in Positive and Negative Syndrome Scale total score is the primary endpoint.<\/p>\n This is a neutral, moderate-importance leadership signal. The appointment closes a disclosed CMO search and provides domain-relevant clinical leadership ahead of a pivotal readout. The strongest interpretation is continuity rather than a change in strategy; appointment credentials cannot substitute for randomized data.<\/p>\n Importance:<\/strong> 3\/5 \u00b7 Direction:<\/strong> Neutral \u00b7 Confidence:<\/strong> High on facts, Low-moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":" LB Pharmaceuticals appointed Susan G. Kozauer, M.D., chief medical officer effective September 14 and announced the appointment on September 15. She succeeds Anna Eramo, M.D., who resigned as CMO effective June 15 for personal…<\/p>\n","protected":false},"author":1,"featured_media":3172,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,196],"tags":[762,763],"class_list":["post-3156","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-leadership-tracker","tag-lb-pharmaceuticals","tag-schizophrenia"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3156"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3156\/revisions"}],"predecessor-version":[{"id":3182,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3156\/revisions\/3182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3172"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
\n Factor<\/th>\n Assessment<\/th>\n<\/tr>\n \n Succession Timing<\/td>\n Kozauer started September 14, one day before Eramo’s disclosed consulting period ended \u2014 a narrow but planned continuity window<\/td>\n<\/tr>\n \n Predecessor Status<\/td>\n Eramo resigned for personal reasons effective June 15; departure said unrelated to clinical operations or practices; next destination undisclosed<\/td>\n<\/tr>\n \n Execution Milestone<\/td>\n NOVA 2 topline results expected H1 2027, placing the new CMO in role during final study conduct, analysis and regulatory planning<\/td>\n<\/tr>\n \n Role Fit<\/td>\n Prior development work in schizophrenia, mood disorders and pediatric neuropsychiatry at Centessa and Intra-Cellular Therapies<\/td>\n<\/tr>\n \n Falsification Test<\/td>\n Continuity should be reassessed if trial timing changes, material protocol or safety disclosures emerge, or transition-related execution effects are identified<\/td>\n<\/tr>\n<\/table>\n InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n